ProStrakan Group plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ProStrakan Group plc
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.
Reapplix’s CEO tells Medtech Insight the Danish group now has the funds to launch its biological wound healing patch in the US for treating patients with diabetic foot ulcers.
The evolution of how and where patients receive their care has received an unexpected boost from the COVID-19 crisis. Coronavirus volume testing challenges persist, but the global medtech industry is now looking beyond the crisis toward a return to “normal” business.
South Korea, one of the first countries to be hit by the spread of COVID-19 from China, has implemented new standalone IVD regulations.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Strakan Pharmaceuticals, Ltd.